Does It Make Sense to Listen to Stock Analysts? Evidence from the Polish Market

2013 ◽  
Author(s):  
Adam Zaremba ◽  
Przemyslaw Konieczka
Keyword(s):  
Stock Analysts

scholarly journals Do Stock Analysts Influence Merger Completion? An Examination of Postmerger Announcement Recommendations

2015 ◽  
Vol 61 (10) ◽  
pp. 2430-2448 ◽  
Author(s):  
David A. Becher ◽  
Jonathan B. Cohn ◽  
Jennifer L. Juergens
Keyword(s):  
Stock Analysts

The value of stock analysts' recommendations: Evidence from emerging markets

2009 ◽  
Vol 18 (1-2) ◽  
pp. 74-83 ◽  
Author(s):  
Fariborz Moshirian ◽  
David Ng ◽  
Eliza Wu
Keyword(s):  
Emerging Markets ◽  
Stock Analysts

When do stock analysts find bond rating changes informative?

2015 ◽  
Vol 46 (1) ◽  
pp. 3-30 ◽  
Author(s):  
Boochun Jung ◽  
Konduru Sivaramakrishnan ◽  
Naomi Soderstrom
Keyword(s):  
Bond Rating ◽  
Rating Changes ◽  
Stock Analysts

The American biodefense industry: From emergency to nonemergence

2007 ◽  
Vol 26 (1) ◽  
pp. 15-23 ◽  
Author(s):  
Filippa Lentzos
Keyword(s):  
United States ◽  
Financial Markets ◽  
The United States ◽  
Biological Weapons ◽  
Capital Funding ◽  
Development Support ◽  
Retained Earnings ◽  
Funding Level ◽  
Stock Analysts ◽  
Disease Focus

Since 1998, and especially since the “Amerithrax” emergency of 2001, the United States has ambitiously funded biodefense projects, intending not only to enhance detection and management of any biological-weapons attack but also to establish a robust domestic biodefense industry. I asked if the United States had fulfilled this latter intention. Using the RAND Corporation's RaDiUS database, I examined federal biodefense grants and contracts awarded from 1995 through most of 2005, noting recipient type, awarding unit, funding level, and the disease focus of research-and-development support. Patterns in these data as well as other sources suggest that the biodefense industry as late as 2005 remained in a nascent stage, with most firms small, precariously financed, and more responsive to funders' announcements and solicitations than to opportunities for self-directed innovation. A biodefense industry with investor-capital funding and retained earnings, with its own leading companies, with its own stock analysts, and with its own legitimacy in commercial and financial markets did not emerge over the period studied, nor does its emergence appear imminent.

Corporate Strategy and Wealth Creation

2002 ◽  
pp. 124-139
Author(s):  
Caron H. St. John ◽  
Nagraj (Raju) Balakrishnan ◽  
James O. Fiet
Keyword(s):  
Financial Performance ◽  
Corporate Strategy ◽  
Decisive Role ◽  
Wealth Creation ◽  
Strategic Decisions ◽  
Executive Management ◽  
Corporate Managers ◽  
Firm Financial Performance ◽  
Economic Trends ◽  
Stock Analysts

Corporate managers, business consultants, stock analysts, and academic researchers have long maintained that the strategic decisions of managers have a direct influence on firm performance. Although societal and economic trends, industry characteristics, and chance all influence performance, the strategic decisions made by managers are believed to play a decisive role in shaping financial performance. Even so, researchers investigating this relationship have reported largely ambiguous results (Rumelt, 1974; Ramanujam and Varadarajan, 1989; Hoskisson and Hitt, 1990; Robbins and Pearce, 1992; Markides and Williamson, 1994; Barker, 1994). Furthermore, attempts by analysts to forecast future financial performance by scrutinizing current strategy decisions have been plagued with problems. Can firm financial performance be predicted with accuracy from the corporate strategy decisions of the executive management team?

Sign in / Sign up

Export Citation Format

Share Document